Our 2014 approach to breakthrough invasive fungal infections

Georg Maschmeyer, Thomas F. Patterson

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Summary: Evidence-based clinical pathways to direct antifungal treatment options in patients with breakthrough fungal infections during current systemic antifungal therapy are not available. Nonetheless, for defined settings of such breakthrough infections approaches to management can be recommended based on clinical, epidemiological, pharmacological and in vitro susceptibility data.

Original languageEnglish (US)
Pages (from-to)645-651
Number of pages7
Issue number11
StatePublished - Nov 1 2014


  • Breakthrough fungal infection
  • Echinocandins
  • Fluconazole
  • Liposomal AmB
  • Posaconazole
  • Voriconazole

ASJC Scopus subject areas

  • Infectious Diseases
  • Dermatology


Dive into the research topics of 'Our 2014 approach to breakthrough invasive fungal infections'. Together they form a unique fingerprint.

Cite this